$40.56 0.05 (0.12%)
11:04 EST PFE Stock Quote Delayed 15 Minutes
Previous Close $40.61
Market Cap 237.26B
PE Ratio 11.27
Volume (Avg. Vol.) 6.28M
Day's Range 40.50 - 40.81
52-Week Range 33.97 - 44.56
Dividend & Yield 1.36 (3.35%)
PFE Stock Predictions, Articles, and Pfizer News
- From InvestorPlace
- From the Web
Pfizer stock offers good value to patient investors. Pfizer's new spinoffs will provide a higher total return to the owners of Pfizer stock.
Tuesday's big stock charts focus on 3 value plays that are looking to continue recent breakouts.
The December jobs report was't as strong as economists expected and that triggered some modest selling on Wall Street to close the week.
Pfizer stock has no momentum right now. Earnings and revenue are in decline and the charts are struggling. I would avoid for now.
FDA approval of Vascepa in use for cardiovascular events just widened Amarin’s revenue potential. Amarin stock should have a banner 2020.
By Thomas Niel
Wall Street has discounted Pfizer's divestiture plans. But spinning off off-patent drugs could improve the valuation of PFE stock.
These 10 stocks had an ugly 2019 — but the outlook for 2020 looks much brighter.
By Ian Cooper
With another year in the history books, investors are turning to popular year-end strategies. With that said, one of my personal favorites is the Dogs of the Dow.
These nine stocks to buy all look too cheap. In this expensive market, they could be among the best stocks to invest in right now.
The lagging healthcare sector has been building momentum and that boosted the Dow Jones Industrial Average today.
Friday's 3 big stock charts highlight 3 names looking for help from a market at all-time highs.
There's a strong case for investing in Pfizer stock. With a great deal of uncertainty in the near-term, however, some patience with PFE stock may be required.
Cara stock is up ahead of its presentations at Kidney Week 2019. Unless it reports bad news, Cara Therapeutics looks ready to run.
GrubHub, Shopify, Apple, Pfizer and General Motors were our top stock trades from Tuesday. Here's a look at the charts.
Akcea Therapeutics (AKCA) stock is flying high on Monday following news of a $250 million deal with Pfizer (NYSE:PFE) for licensing rights.
From Market News Video
The latest tally of analyst opinions from the major brokerage houses shows that among the 30 stocks making up the Dow Jones Industrial Average, Pfizer (PFE) is the #19 analyst pick. Despite being ranked lower than the median among analyst picks of the Dow, Pfizer Inc ranks better than the median among analyst picks for the broader S&P 500 index components, claiming the #244 spot out of 500.
Navellier RatingsPowered by Portfolio Grader